Glycan Analysis by MALDI-MS in Negative Ion Mode
Shinichi Iwamoto
Professor David J. Harvey of the University of Oxford introduced many papers of our laboratory in the recent review for glycan mass spectrometry. (David J. Harvey: Mass Spectrometry Reviews, 39, 589-679. 2020)
Fukuyama, Kaneshiro, Sekiya and Nishikaze are first authors of the papers introduced in the review. In their papers, MALDI matrices, additives, and derivatization for glycan analyses are reported.
In particular, Nishikaze’s papers are cited so many, up to nine. The main contents are 1) high sensitivity by derivatization of glycan, 2) structural analysis of branched glycan by negative ion MS/MS, and 3) isomer discrimination by linkage-specific derivatization of sialic acid.
Glycans as well as proteins are compatible compound for MALDI-MS. Our laboratory has investigated in glycan analysis using MALDI-MS since the establishment in 2003.
[Review information] : David J. Harvey: ‟Negative Ion Mass Spectrometry for the Analysis of N-Liked Glycans”: Mass Spectrometry Reviews, 39, 589 -679. 2020: DOI 10.1002/mas.21622
[Reference information] : Takashi Nishikaze: “Sensitive and structure-informative N-glycosylation analysis by MALDI-MS.; Ionization, fragmentation, and derivatization”: Mass Spectrometry, 6: A0060.2017: https://doi.org/10.5702/massspectrometry.A0060
Note: This column was originally published on LinkedIn in October 2020. Affiliations and titles are as of that time.
Shinichi Iwamoto, PhD
Deputy General Manager, Koichi Tanaka Mass Spectrometry Research Laboratory
Shinichi Iwamoto joined Shimadzu Corporation in 1991. As a research and development team for biometrics, he developed near-infrared brain function measurement devices and applied research. He was a founding member of the Koichi Tanaka Mass Spectrometry Research Laboratory, established in 2003. Since then, he has been involved in developing elemental technology and applied research of MALDI-MS. He became Deputy General Manager in 2014. He has been engaged in designing fundamental technologies for new mass spectrometers, methods for microbial analysis, and disease biomarkers for cancer and Alzheimer's disease.
